

Supplementary Table 2. Subgroup analysis of nasal symptoms

	Nasal congestion for 1 month	Nasal congestion for 3 months	Facial pain for 1 month	Facial pain for 3 months	Olfactory dysfunction for 1 month	Olfactory dysfunction for 3 months	Rhinorrhea for 1 month	Rhinorrhea for 3 months
Overall symptoms score	MD -0.3903, 95% CI [-0.4218; -0.3589]; I ² =0.0%	MD -0.3657, 95% CI [-0.4652; -0.2662]; I ² =69.8%	MD -0.2225, 95% CI [-0.2474; -0.1975]; I ² =0.0%	MD -0.1545, 95% CI [-0.2442; -0.0648]; I ² =73.4%	MD -0.1800, 95% CI [-0.2248; -0.1353]; I ² =62.8%	MD -0.2660, 95% CI [-0.3214; -0.2107]; I ² =55.1%	MD -0.3429, 95% CI [-0.4008; -0.2851]; I ² =59.6%	MD -0.2974, 95% CI [-0.3757; -0.2191]; I ² =58.0%
93 µg	n=2 MD -0.3180, 95% CI [-0.4631; -0.1729]; I ² =0.0%		n=2 MD -0.2097, 95% CI [-0.3548; -0.0646]; I ² =0.0%		n=2 MD -0.2092, 95% CI [-0.3412; -0.0773]; I ² =0.0%		n=2 MD -0.3495, 95% CI [-0.5016; -0.1974]; I ² =0.1%	
186 µg	n=4 MD -0.3792, 95% CI [-0.4251; -0.3332]; I ² =13.0%	n=2 MD -0.3102, 95% CI [-0.4461; -0.1744]; I ² =70.2%	n=4 MD -0.1996, 95% CI [-0.2331; -0.1661]; I ² =0.0%	n=2 MD -0.1338, 95% CI [-0.3097; 0.0422]; I ² =84.8%	n=4 MD -0.1472, 95% CI [-0.2260; -0.0685]; I ² =71.0%	n=2 MD -0.2258, 95% CI [-0.2748; -0.1769]; I ² =5.8%	n=4 MD -0.3383, 95% CI [-0.4466; -0.2300]; I ² =75.1%	n=2 MD -0.2696, 95% CI [-0.4163; -0.1230]; I ² =77.3%
372 µg	n=4 MD -0.4081, 95% CI [-0.4532; -0.3629]; I ² =0.0%	n=2 MD -0.4184, 95% CI [-0.4997; -0.3372]; I ² =0.0%	n=4 MD -0.2537, 95% CI [-0.2924; -0.2151]; I ² =0.0%	n=2 MD -0.1798, 95% CI [-0.2957; -0.0639]; I ² =63.3%	n=4 MD -0.2022, 95% CI [-0.2331; -0.1714]; I ² =0.0%	n=2 MD -0.3145, 95% CI [-0.3726; -0.2565]; I ² =0.0%	n=4 MD -0.3512, 95% CI [-0.4444; -0.2581]; I ² =63.6%	n=2 MD -0.3294, 95% CI [-0.4043; -0.2544]; I ² =0.0%
p value	0.4115	0.1804	0.1147	0.6682	0.4340	0.0221	0.9834	0.4770

MD, mean difference; CI, confidence interval.